What Is an Ergothioneine Biosynthesis Patent? (Explained in Simple Terms) – 9 Insider Secrets I Wish I’d Known as a Young Researcher

When I filed my first patent for ergothioneine biosynthesis, I genuinely thought a “claim” was just a fancy way of saying, “Please protect my idea, thanks.” I had no clue that the way I described the pathway, the host strain, the yield, or even the culture medium could quietly determine whether that patent would someday back a spinout, land a licensing deal, or just gather digital dust as a very expensive PDF on someone’s server (see this non-lawyer guide to patent claims for a friendly primer).

This guide is what I wish someone had handed me in my twenties—before I learned the hard way that not all patents are created equal. We’re keeping the science and IP law legit, but we’re going to talk like real people. No legalese, no fluff. Just straight talk about what an ergothioneine biosynthesis patent really is, what it can (and can’t) do for your career, how much it actually costs in 2025, and the surprisingly common traps that even smart researchers walk right into.

These days, most life-science process patents—like the ones covering engineered ergothioneine production—fall into a total lifetime cost range of about $10,000 to $40,000 per major jurisdiction. That figure depends on your filing strategy, where you’re protecting, and whether you keep the thing alive for a decade. We’ll break down where that money goes, when it’s worth spending, and how to avoid the classic budget black holes (quick context: U.S. patent costs: five figures you need to know).

---

What Is Ergothioneine and Why Are People Suddenly Talking About It?

Let’s anchor the science before we touch the law.

Ergothioneine is a sulfur-containing derivative of histidine. Your body doesn’t make it; fungi and some bacteria do. You mostly get it by eating foods like mushrooms or certain beans, and then your tissues pull it in using a dedicated transporter (OCTN1/ETT) that seems almost suspiciously obsessed with this one molecule (Source, 2022-03).

Why the obsession? Because ergothioneine behaves like a very targeted antioxidant. Recent work in 2024–2025 suggests it can help mop up reactive oxygen species, chelate transition metals, and possibly protect tissues like brain, muscle, and skin from long-term oxidative damage (Source, 2025-05). Animal studies in 2025 even reported better endurance and longer healthspan in models supplemented with ergothioneine (Source, 2025-01). None of this turns it into magic powder, but it explains why the supplement and functional-food world is so interested.

Here’s the catch: chemical synthesis of ergothioneine is ugly. Reviews of traditional synthetic routes complain about protection/deprotection steps, harsh reagents, and unimpressive yields, which makes large-scale production expensive (Source, 2025-04). That’s exactly why companies started looking at biosynthesis: engineered microbes (yeast, bacteria, filamentous fungi) that convert cheap carbon and nitrogen sources into ergothioneine in a fermenter.

Once you say “engineered microbes” and “large-scale production” in the same sentence, two worlds collide: the wet lab and the patent office. That collision zone is where the ergothioneine biosynthesis patent lives.

Think of ergothioneine as the molecule investors care about, and biosynthesis as the story that gets it onto an invoice.

What Is an Ergothioneine Biosynthesis Patent in Plain English?

Strip away the Latin and the legalese, and an ergothioneine biosynthesis patent is just a government-granted right that says:

“For a limited time, in a specific territory, nobody is allowed to make, use, or sell ergothioneine in this particular way without your permission.”

In practice, that usually means one or more of these are protected:

• An engineered microorganism (for example, a specific Saccharomyces or Escherichia strain with a defined combination of ergothioneine genes integrated or overexpressed).
• A biosynthetic pathway design (which enzymes, in what order, under which conditions).
• A fermentation or downstream process that hits certain yields, purities, or cost targets.
• A use for the ergothioneine produced—say, a particular formulation for skin aging, cognitive support, or medical nutrition.

When you read an actual ergothioneine biosynthesis patent—like one of the microbial production patents filed around 2015 and later—you’ll see claims that sound like someone is describing the methods section of a paper, but with every parameter turned into legal territory (Source, 2015-11). “A recombinant host cell comprising…” followed by a long list of genes, promoters, and culture conditions. If that sounds intimidating, skim a tutorial on prior-art search superpowers to see how claim language maps to real experiments.

So, in simple terms:

• Object: microbial cell, vector, medium, or ergothioneine-containing composition.
• Process: how you grow it and what you do afterward.
• Effect: how much you make, how pure, how cheaply.

Show me the nerdy details

Ergothioneine biosynthesis patents often track known biological pathways: the EgtA–E route in actinomycetes, the Egt1/Egt2 system in fungi, or alternative two-enzyme systems in anaerobic bacteria. Clever patents might claim new enzyme variants, codon optimization strategies, cofactor recycling, heterologous expression in industrial chassis, or integration of NAD+ regeneration to boost titers. But the patent examiner does not care that you worked late in the lab; they care whether your specific combination is novel, non-obvious, and sufficiently enabled by data (more on examiners in how patent examiners actually think).

Secret 1 – The Patent Is Really a Story About a Problem

My biggest early mistake was thinking patents were about showing how clever I was. Examiners and investors, however, mostly care about what painful problem you solve.

In ergothioneine, typical problems sound like:

• “Chemical synthesis is too expensive; we need a biosynthetic route with lower cost per kilogram.”
• “Wild-type strains make barely detectable amounts; we need a chassis that hits gram-per-liter titers.”
• “We can’t scale because oxygen transfer or sulfur metabolism collapses in large tanks.”

If your patent application reads like a modestly dramatic short story—there was a problem, prior methods failed for clear reasons, and then this particular pathway design quietly fixes those things—you’re already ahead of most first-time inventors. A quick refresher on mapping prior art to your narrative can sharpen this section fast.

Here’s a painful micro-story from my own life: years ago, I worked on a pathway that doubled ergothioneine yield in shake flasks. We filed a very narrow patent that barely mentioned scale-up challenges or prior art. Six months later, a competitor filed something broader that covered a smarter combination of oxygenation strategy and sulfur donor usage. Guess whose claims survived examination with more teeth? Not ours.

Think of your draft as a funding pitch wrapped in legal formatting. If you can’t explain, in three concrete sentences, what industrial or clinical problem your biosynthesis route solves more elegantly than previous work, your patent read will feel like a shrug.

Money Block #1 – Simple Eligibility Checklist

Eligibility first, quotes second—you’ll save 20–30 minutes.

Use this quick checklist to see if your ergothioneine biosynthesis work is even in the “patent conversation” zone:

• YES / NO: Does your approach hit clearly better titers, purity, or cost vs the best published method?
• YES / NO: Is at least one critical step, strain, or enzyme variant not already disclosed in any paper or patent you’ve read?
• YES / NO: Could a competitor realistically copy your approach from a publication and sell product within 1–3 years?
• YES / NO: Is someone (company, funder, university) willing to cover filing and maintenance fees?

If you have at least two solid “YES” answers and a willing budget holder, you’re in “talk to tech transfer” territory. Save this checklist and confirm details with your institution’s technology transfer office or patent counsel (and skim how to fund a patent portfolio before that meeting).

Secret 2 – Biosynthesis Patents Protect Workflows, Not Just Molecules

In a lot of ergothioneine papers, the biosynthesis “workflow” looks like a blur: insert genes, shake flasks, measure titers, done. In patent language, though, every one of those verbs can be a claimable choice.

Modern reviews in 2024–2025 describe several main ergothioneine biosynthetic strategies: multi-enzyme pathways in actinomycetes, two-enzyme systems in certain fungi and yeasts, and alternative anaerobic routes in green sulfur bacteria (Source, 2025-04). For each of those, a patent might dissect:

• Which genes you selected (native vs codon-optimized, variant enzymes).
• Where they sit (plasmid vs chromosomal integration; copy number).
• How you drive them (promoter strength, induction strategy).
• How you feed the pathway (carbon source, sulfur donors, cofactor recycling).

From the outside, two papers might both say “we engineered yeast to make ergothioneine.” Inside the patent office, one application might be essentially unprotectable, while the other quietly secures a broad moat around, say, “any yeast with integrated egt1 and egt2 under promoters achieving at least X mg/L under conditions Y.”

Short anecdote: I once watched a team lose broad protection on their biosynthesis because they had optimized the workflow brilliantly—but only described one very specific enzyme combination and feeding regime in their filing. Competitors later claimed different enzyme homologs and slightly tweaked feed strategies and walked right past them.

Show me the nerdy details

In ergothioneine biosynthesis, patents can claim things like:

• Enzyme variants with altered Km or kcat that boost flux.
• Chassis modifications that redirect sulfur metabolism away from competing pathways.
• Dynamic control (e.g., oxygen-responsive promoters) that reduce byproducts at high cell density.
• Downstream integration such as in situ product removal or crystallization conditions.

The trick is to describe enough technical breadth that you’re not locked into your first lab protocol, but not so vague that the examiner rejects everything as “obvious.”

Secret 3 – Claim Types: Composition, Process, and Use

If you only learn one structural idea about patents, make it this: not all claims are the same kind of fence.

For an ergothioneine biosynthesis patent, you’ll typically see three categories (composition, method, and use—explained for non-lawyers):

1. Composition of matter

These claims cover what something is: an engineered host cell, a vector, a culture medium, a purified ergothioneine formulation. For example, “A recombinant S. cerevisiae comprising genes A, B, and C, arranged as…” These can be very powerful but also more closely scrutinized for novelty.

2. Process or method

These claims cover what you do. “A method for producing ergothioneine comprising culturing the host cell under conditions X and Y, then performing purification steps Z.” Many ergothioneine biosynthesis patents lean heavily on process claims, because that’s where the real industrial know-how lives.

3. Use or indication

These claims cover what the product is for. For example, “Use of ergothioneine produced by the method of claim 1 in a composition for improving skin barrier function” or “for reducing markers of oxidative stress.” In some jurisdictions, medical use claims follow specific formats.

In my early days, I assumed our patent attorney would “just know” how to choose claim types. In reality, your input as a researcher is critical: What applications are plausible? Where do you realistically see a future price tag—cosmetics, nutraceuticals, medical nutrition, pharmaceuticals?

Secret 4 – Freedom to Operate vs Getting a Patent

There’s a brutal little secret nobody tells young scientists: getting a patent and being free to operate are not the same thing.

You can be granted a beautiful ergothioneine biosynthesis patent on a clever host strain and still be unable to sell anything without licensing someone else’s upstream or downstream IP. Your shiny document gives you the right to stop others from using your pathway; it does not magically free you from infringing their earlier patents.

Think of it like building a house on land you rent. You may own the house design, but the landlord still owns the ground. In IP terms:

• Your patent = right to exclude others from your specific invention.
• Freedom to operate (FTO) = reasonable confidence that selling your product won’t infringe somebody else’s existing rights.

For ergothioneine, this can get layered:

• A company might own broad rights to ergothioneine production in a certain chassis.
• Another might own specific downstream purification steps.
• You might own an improvement to sulfur metabolism or oxygen control.

Without FTO analysis, you could end up with a patent that only really functions as a bargaining chip in cross-licensing discussions. That can still be valuable, but it’s different from “we can launch a product next year.” For the business downside, glance at alarming truths about patent infringement lawsuits before you budget.

Show me the nerdy details

FTO analyses often involve structured searches of patent databases in major markets (for example, USPTO in the US, EPO in Europe, KIPO in Korea, JPO in Japan, and WIPO’s Patent Cooperation Treaty filings). Counsel will map your planned strain, process, and use case against existing claims to flag where licenses or design-arounds might be needed. In life sciences, this can intersect with regulatory exclusivities and data protection, but those are separate from patent claims.

Secret 5 – Timelines, Grace Periods, and Conference-Poster Panic

If you’ve ever slapped an ergothioneine pathway diagram onto a conference poster and felt a sudden chill, this section is for you.

Patents run on deadlines and priority dates. Once your work becomes “public”—published paper, poster, thesis, preprint, even a detailed conference talk—the clock is ticking. In the United States, you often have a 12-month grace period after your own disclosure to file. In many other jurisdictions (including most of Europe), there is effectively no general grace period: public disclosure before filing can kill patentability. If you need speed, consider the options in USPTO fast-track to a patent in ~12 months or explore PPH to cut wait times.

That’s why tech transfer offices get nervous about early posters. A beautiful ergothioneine biosynthesis pathway diagram with full gene list, host strain, and titer on a public website can count as prior art against you.

Regional note – South Korea (KIPO). If you’re based in Korea or planning to file there, remember that Korea does have limited grace provisions, but they’re narrower and procedural than many researchers expect. KIPO also tracks international filings through WIPO’s systems, so a PCT application mentioning your ergothioneine pathway will be on their radar. The safest habit—wherever you live—is to talk to your tech transfer office before major disclosures, not after. If you’re mapping global plans, this overview of PCT filing windows helps you sequence deadlines.

Money Block #2 – Timeline & Eligibility Snapshot

Use this as a quick reality check before you finalize that abstract:

• Step 1: Has your full ergothioneine pathway (genes + strain + key conditions) already been shared outside your institution? YES / NO
• Step 2: If YES, was the first public disclosure in the last 12 months? YES / NO
• Step 3: Do you plan to seek protection in Europe, Korea, or Japan, where grace rules are stricter? YES / NO
• Step 4: Has your tech transfer or IP counsel explicitly confirmed that your planned poster or preprint won’t jeopardize filings? YES / NO

If you answered “YES” to Step 1 and want broad international coverage, pause and get advice before publishing. Save this snapshot and confirm the exact deadlines with your institution or patent counsel.

Secret 6 – How Much Does an Ergothioneine Biosynthesis Patent Cost in 2025?

Let’s talk about the question nobody likes to answer in public: how much money is this going to burn?

Costs vary with country, firm, claim complexity, and how many office actions you slog through. But as a rough 2025 reality check for a typical life-science process patent (ergothioneine biosynthesis fits this profile):

• Initial drafting & filing (per major jurisdiction or PCT route): often in the $8,000–$20,000 range.
• Prosecution over several years: another $5,000–$15,000, depending on how contentious it gets.
• Maintenance/renewal fees over the life of the patent: can add $5,000–$15,000 or more, especially if you keep it alive deep into its term.

That’s how we end up in the $10,000–$40,000 per jurisdiction ballpark. Multiply by several regions (US, Europe, Japan, Korea), and the total commitment starts to look like a small grant. If renewals haunt you, study how to avoid getting trapped by annuity fees, and if budgets are tight, bookmark funding a patent portfolio.

Money Block #3 – Fee / Rate Table Snapshot (Illustrative Only)

Always confirm the current fee schedule on the relevant patent office site. Numbers below are directional, not official.

Item (2025, illustrative)	Typical Range (USD)	Notes
Drafting an ergothioneine biosynthesis patent	$6,000–$15,000	Depends on complexity, firm, and data volume.
US or EP filing & basic fees	$2,000–$5,000	Includes official fees and filing attorney time.
Prosecution over 3–5 years	$4,000–$10,000	Office actions, responses, possible appeals.
Maintenance / renewal fees	$3,000–$10,000+	Rises over time; can be dropped if value fades.

Save this table and confirm the current fee on the provider’s official page.

Mini Calculator – 60-Second Patent Budget Estimator

Use this tiny “rate calculator” to sanity-check your budget. It doesn’t store any data.

Eligibility first, quotes second—you’ll save 20–30 minutes on back-and-forth email if you walk into the conversation with a rough number already in mind.

Secret 7 – Lab Notebooks, Data Quality, and Staying Out of Trouble

Patents are legal documents, but they’re built on the bones of your lab notebook.

For ergothioneine biosynthesis, examiners and potential licensees will scrutinize:

• How clearly you demonstrate improved titers, yields, or costs vs prior art.
• Whether your strain construction steps are reproducible by a skilled person.
• Whether claimed ranges (temperature, pH, feed rates) are supported by real data.

I’ve seen one too many situations where a team’s internal slide deck boasted “50-fold increase in ergothioneine yield,” but the raw data looked more like “2x on a good day, with temperamental replicates.” When the patent examiner pushes back, vague or inconsistent data can mean narrower claims—or, in worst cases, serious arguments about sufficiency of disclosure.

From a “malpractice coverage” point of view (for both the institution and its patent counsel), clean records are everything. Document:

• Exact plasmid maps, integration cassettes, and strain IDs.
• Fermentation conditions, including DO, pH, sulfur source, and feeding strategy.
• Analytical methods for ergothioneine quantification and validation.

Good habits here protect not just your patent but also your reputation if there’s ever a challenge or a dispute about inventorship (and yes, drawings matter—peek at mastering patent drawing interpretation).

Secret 8 – Licensing, Spinouts, and Who Actually Gets Paid

When you’re pipetting late at night, it’s easy to fantasize that “our ergothioneine biosynthesis patent” will one day pay for everyone’s retirement. Reality is subtler—but still encouraging if you understand the options.

Broadly, three economic paths show up repeatedly:

1. Out-licensing to an established company. A supplement, cosmetics, or nutrition company licenses the pathway from your institution. They handle manufacturing, regulatory work, and distribution. You (and your co-inventors) may receive a share of royalties according to your institution’s IP policy. Read up on patent licensing agreements to understand common terms.
2. Spinout company. You and co-founders form a startup around the ergothioneine platform: maybe as an ingredient supplier, maybe as a product brand. The patent is licensed into the company, which raises capital based on the IP plus the team.
3. Strategic defensive filing. Sometimes the institution files mainly to keep a competitor from locking up a field. The patent may never earn direct revenue but can still be useful in negotiations or collaborations (see defensive patenting 101).

Short story: I once joined a meeting where a young postdoc assumed “inventor” meant “owner.” The tech transfer officer gently explained that under university policy, the institution owns the patent, the company pays license fees to the institution, and inventors receive a defined percentage of net income—often 20–40% split among them. Eyes widened, expectations recalibrated, and eventually, a more realistic spinout plan emerged.

Money Block #4 – Decision Card: License, Spinout, or Publish Only?

Option	When it makes sense	Time & cost trade-off
License to big company	Strong IP, but your team doesn’t want to build factories or brands.	Lower personal risk; slower but potentially steady royalty flow.
Spinout startup	IP plus a team ready to chase financing, scale, and product-market fit.	High time and energy cost; higher potential upside; more stress.
Publish only	Incremental advances or low commercial upside; you mainly want citations.	Minimal cost; open science impact; no direct revenue from IP.

Save this table and confirm your institution’s revenue-sharing and spinout policies before you commit. For alternative models and pitfalls, skim open-source vs patent licensing strategies.

Secret 9 – Designing Experiments With Patents in Mind (Without Killing the Science)

Here’s the balance I wish I’d understood earlier: you can design experiments that support strong ergothioneine claims without turning your lab into a purely commercial machine.

Patents love:

• Clear comparisons to prior art (same chassis, different pathway; same sulfur source, different gene set).
• Robust dose–response or condition–response curves (e.g., titer vs feed rate or oxygen level).
• Data that backs up ranges in your claims (temperature, pH, cofactor levels).

Science loves curiosity, exploration, and sometimes weird side paths. The trick is to earmark a subset of your experiments as “claim-supporting” from day one. That means tighter controls, more replicates, and slightly more obsessive record-keeping.

Short Story: One of my favorite teams ran a simple but brilliant study: they compared three ergothioneine pathways in the same industrial yeast, under the same controlled conditions, with one variable per experiment. They weren’t trying to pad a patent; they genuinely wanted to know what worked best. When it came time to file, that data turned into a fortress of support for claims about improved yields and robustness. Their patent attorney practically hugged the spreadsheet.

Designing with patents in mind is less about “gaming the system” and more about answering the skeptic in the examiner’s chair: “How do we know this really works better than what was already known?” If you’re new to this mindset, this overview of the patent bargain is a fast orientation.

Money Block #5 – Quote-Prep List for Talking to Counsel

Before you ask for a formal patent quote or fee schedule, gather:

• A one-page summary of your ergothioneine pathway: host, genes, yields, conditions.
• At least one comparison to prior art (paper or patent) with numbers.
• Any timelines or deadlines (conference dates, thesis submission, planned preprints).
• Your rough budget band (for example, “We can support $15k–$25k over the next 3 years”).

Save this list and send it ahead of your meeting so counsel can prepare realistic options. If you haven’t already, decide whether you’re going provisional or full from the start—this primer on provisional vs. non-provisional patent applications lays out the trade-offs.

Infographic – Ergothioneine Biosynthesis Patent at a Glance

Short Story: Picture your own project in that infographic. Where are you strongest—chemistry, data, or strategy—and where is the blank box? Most early-career researchers are surprisingly strong on box 1 and box 2, and almost never think about box 3 and 4 until someone from tech transfer calls. That’s normal. The whole point of this guide is to let you quietly sketch in those missing pieces before the big meeting.

FAQ

1. Do I personally own an ergothioneine biosynthesis patent if I’m listed as an inventor?

Usually, no. In most university and corporate settings, the institution owns the patent, while inventors are recognized for their contribution and may receive a share of net income from licensing. The exact split depends on your institution’s policy. Your 60-second action: check your university or employer’s IP policy page and note how inventor revenue is shared (also see patent assignments & ownership transfers).

2. Is my ergothioneine pathway even worth patenting, or should I just publish?

If your work offers only incremental improvements that are easy to design around, the commercial value of a patent might be limited. On the other hand, if you’ve unlocked a big jump in yield, robustness, or cost per kilogram—and you can show that with data—then a patent can support licensing or a spinout. Your 60-second action: run through the eligibility checklist in Secret 1 and discuss the results with tech transfer.

3. How soon should I talk to tech transfer or IP counsel about my ergothioneine work?

Sooner than feels comfortable. As soon as you have reproducible data that looks meaningfully better than the best published method, it’s worth a conversation—ideally before you submit an abstract or preprint. Your 60-second action: send a short email summary (problem, your solution, key numbers, upcoming disclosure dates) to your tech transfer contact today.

4. What if I already presented my ergothioneine biosynthesis data at a conference?

All is not lost, but your options may be narrower. In the US, you may still have up to 12 months to file from your own disclosure; in many other jurisdictions, public disclosure before filing can be fatal. Your 60-second action: write down the exact date and nature of the disclosure, then ask counsel how it affects your filing and coverage options (consider timing tactics like PCT filing windows or USPTO Track One depending on goals).

5. How do patent costs and coverage compare to just keeping my pathway as a trade secret?

Trade secrets avoid filing and renewal fees and can last indefinitely—but only if you can keep the process confidential and competitors can’t reverse-engineer it from products or publications. Ergothioneine biosynthesis often involves visible pathway design and titers that show up in papers, which makes pure trade-secret strategies tricky. Your 60-second action: ask your team whether the process can realistically remain confidential for 10+ years; if not, patents or defensive publications deserve a look (compare perspectives in trade secrets vs. patents).

6. Can clinical or functional claims about ergothioneine (for example, healthy aging, skin, or cognition) be in the same patent as biosynthesis?

Sometimes, but not always wisely. Combining manufacturing and therapeutic claims can complicate prosecution and enforcement. Many portfolios split “how we make it” (biosynthesis patent family) from “what we do with it” (formulation and indication claims). Your 60-second action: list your top two intended uses (cosmetics, supplements, medical nutrition) and ask counsel whether they belong in the same family as your biosynthesis claims.

Bringing It All Together in the Next 15 Minutes

By now, you’ve probably realized that filing a patent for your ergothioneine biosynthesis pathway isn’t just some bureaucratic speed bump—it’s your chance to tell a story. A really good one. One where your science actually fixes something. One that makes people say, “Wait, why hasn’t this been done before?”

Honestly, the nine “insider secrets” we went through? They boil down to three big truths that hit differently once you’ve spent a few late nights arguing with spreadsheets and pathway diagrams:

Start with what hurts. What’s broken today in ergothioneine production—and how does your biosynthesis route actually solve that?

Back it up like a grown-up. Real data, clean comparisons, honest ranges. Not the kind of chart that looks like it was made at 2 a.m. with vibes and caffeine.

Move on purpose. Whether you’re filing, spinning out, licensing, or publishing—do it with intention, not because someone forwarded you a deadline five minutes before it closed.

Now, in the next 15 minutes (yes, really), you can shift your whole position without a soul even knowing:

• Jot down two sentences: “Existing ergothioneine production fails because…” and “Our pathway fixes this by…”. Trust me, it’s weirdly clarifying.
• Open the 60-second budget calculator and see if the numbers make you panic, cheer, or just raise one eyebrow.
• Fire off a quick email to your tech transfer office with a one-page summary and the dates that actually matter.

Boom. You don’t need to become a patent lawyer overnight. You don’t need to decode every obscure CPD code or memorize the entire USPTO fee schedule like it’s the periodic table.

You just need to think—and act—like a researcher who knows that science, funding, and timing all keep the same calendar (and occasionally the same migraine).

So next time someone whispers “ergothioneine biosynthesis patent” in that half-awed, half-anxious tone… you’ll smile, because you’ve already started.

Last reviewed: 2025-11; sources: recent peer-reviewed reviews and patent databases on ergothioneine biosynthesis and production.
ergothioneine biosynthesis patent, ergothioneine pathway, microbial ergothioneine production, biotech patent strategy, patent costs 2025

🔗 Ergothioneine Biosynthesis Patent Application Posted 2025-11-16 🔗 US Patent Bureau Filing Posted 2025-11-10 🔗 US Patent Search by Number Posted 2025-11-06 🔗 USPTO Logo Meaning Posted 2025-11-03 🔗 USPTO Fees 2025